Hannah Page Bell

Pastorus, Inc. is a biotechnology company based in the United States that is focused on developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Pastorus aims to address the particular need for drugs to treat autism, a disorder that affects over 3 million individuals in the US and tens of millions worldwide. The American company's core team of three physician-neuroscientists, each with over 20 years of industry experience, collaborate with successful experts in regulatory, clinical, manufacturing, and other domains. Recent research has demonstrated the potential to amplify oxytocin's favorable effects with a combination product, for which Pastorus has a pending patent application. The private company was founded by Jim Page and Glenn Cornett, with Glenn Cornett serving as CEO since incorporation.

Pastorus, Inc. is a biotechnology company based in the United States that is focused on developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Pastorus aims to address the particular need for drugs to treat autism, a disorder that affects over 3 million individuals in the US and tens of millions worldwide. The American company's core team of three physician-neuroscientists, each with over 20 years of industry experience, collaborate with successful experts in regulatory, clinical, manufacturing, and other domains. Recent research has demonstrated the potential to amplify oxytocin's favorable effects with a combination product, for which Pastorus has a pending patent application. The private company was founded by Jim Page and Glenn Cornett, with Glenn Cornett serving as CEO since incorporation.

Pastorus, Inc. is a biotechnology company based in the United States that is focused on developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Pastorus aims to address the particular need for drugs to treat autism, a disorder that affects over 3 million individuals in the US and tens of millions worldwide. The American company's core team of three physician-neuroscientists, each with over 20 years of industry experience, collaborate with successful experts in regulatory, clinical, manufacturing, and other domains. Recent research has demonstrated the potential to amplify oxytocin's favorable effects with a combination product, for which Pastorus has a pending patent application. The private company was founded by Jim Page and Glenn Cornett, with Glenn Cornett serving as CEO since incorporation.